ロード中...
Enfortumab Vedotin in urothelial cancer
The treatment landscape for metastatic urothelial cancer (mUC) beyond first-line platinum-based chemotherapy has changed significantly over the last 5 years with the recent approvals of the immune checkpoint inhibitors (ICIs), fibroblast growth factor receptor (FGFR) inhibitors and most recently Enf...
保存先:
| 出版年: | Ther Adv Urol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7780177/ https://ncbi.nlm.nih.gov/pubmed/33447264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287220980192 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|